---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-014153"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:46:57.811637+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio reports 3 patients each enrolled in Phase 1 trials of ADI-001 LN and ADI-270 ccRCC

## Summary
- ADI-001 LN Phase 1: 3 patients enrolled as of Feb 2025; first dosed Nov 2024; ~12 sites activated; preliminary data due H1 2025.
- ADI-001 additional autoimmune indications: Phase 1 enrollment to start Q1 2025 for SLE, systemic sclerosis, IIM, stiff person syndrome; preliminary data H2 2025.
- ADI-270 ccRCC Phase 1: 3 patients enrolled; first dosed Dec 2024; ~7 sites activated; preliminary data expected H1 2025.
- ANCA-associated vasculitis enrollment planned for H2 2025.

## SEC filing metadata
- accession: 0000950170-25-014153
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017025014153/0000950170-25-014153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017025014153/acet-20250205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-014153
- JSON: https://secwatch.observer/filing/0000950170-25-014153.json
- Plain text: https://secwatch.observer/filing/0000950170-25-014153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.